Dengue virus nonstructural protein 5 (NS5) (NS5)

The Dengue virus nonstructural protein 5 (NS5) is the largest and most highly conserved protein within the Dengue virus (DENV) proteome, playing a critical role in viral replication [1][2]. It is a bifunctional enzyme containing an N-terminal S-adenosyl-L-methionine-dependent methyltransferase (MTase) domain and a C-terminal RNA-dependent RNA polymerase (RdRp) domain [2][3]. The MTase domain is responsible for the 5'-capping and methylation of viral mRNA, protecting it from host degradation and facilitating translation, while the RdRp domain synthesizes the viral RNA genome [2][3]. Because NS5 is essential for the viral life cycle and lacks a direct human homolog for its RdRp activity, it is a primary target for the development of direct-acting antivirals [4]. Drugs targeting NS5 generally include nucleoside analogs that act as chain terminators or non-nucleoside inhibitors that bind to allosteric pockets to prevent conformational transitions [4][5]. Effective inhibition of this target is intended to treat Dengue fever and prevent progression to severe forms like Dengue hemorrhagic fever [1]. However, therapeutic development faces challenges such as ensuring efficacy across all four DENV serotypes and avoiding interference with host mitochondrial polymerases [5][6].

Other names

DENV NS5Dengue virus NS5 RNA-dependent RNA polymeraseNS5 RdRp/MTaseDengue virus polymerase

Nucleoside analogs act as competitive inhibitors of natural nucleoside triphosphates, leading to premature RNA chain termination upon incorporation [4][8]. Non-nucleoside inhibitors (NNIs) bind to allosteric sites, such as the thumb-fingers 'N-pocket,' to lock the enzyme in an inactive conformation or prevent the transition from initiation to elongation [5].